China’s Innovative Drugs Are Transitioning from “Import & Imitation” to “Innovation Export,” Entering a High-Quality 2.0 Development Stage

As a long-term participant deeply engaged in the cross-border pharmaceutical supply chain, DengYueMed has clearly observed through real-world business collaboration that China’s innovative drug globalization in 2026 is no longer characterized by sporadic “project out-licensing,” but rather a systematic paradigm shift toward “global healthcare collaboration.” Transaction structures are becoming increasingly complex, regional rights allocation more refined, and globally coordinated regulatory and supply chain systems are becoming the new norm.

The defining feature of this transformation is clear: China’s innovative pharmaceutical industry is moving from “import and imitation” to comprehensive “innovation export,” entering a high-quality 2.0 development stage.

I. Data Signals an Inflection Point: From “Single Breakthroughs” to “Exponential Growth”

Market data at the beginning of 2026 provides strong evidence of this industry upgrade. As of late March, the total value of outbound licensing (BD) deals for Chinese innovative drugs has exceeded USD 53 billion, reaching nearly 40% of the full-year total for 2025 (approximately USD 135.6 billion) in less than one quarter.

This surge is no coincidence. According to Kaiyuan Securities, the period from 2017 to 2026 represents a “golden decade” during which Chinese pharmaceutical companies gained global recognition. The total value of License-out deals surged from USD 2.562 billion to the hundred-billion-dollar level, achieving exponential growth. Both the breadth and depth of global healthcare collaboration continue to expand. Notably, upfront payments in early 2026 have increased by over 1000% year-on-year, indicating that multinational corporations (MNCs) are not only willing to pay for “future potential,” but are now paying a premium for “current certainty.”

II. Structural Upgrade: From License-out to Global Healthcare Collaboration

If Phase 1.0 was dominated by single-asset licensing, then Phase 2.0 is defined by multi-dimensional collaboration driven by global healthcare partnerships.

Recent deal structures reveal several clear trends:

1. Multi-asset and Platform-based Deals

Collaborations are no longer limited to individual molecules but extend to entire technology platforms and pipeline portfolios, such as:

• Full-platform licensing of ADCs and bispecific antibodies

● Combination deals involving small molecules and biologics2. Co-development Becomes Mainstream

An increasing number of partnerships involve:

• Joint execution of global clinical trials

● Regional rights segmentation (e.g., US–EU–China market splits)3. Deeply Aligned Incentive Structures

Deal structures have evolved from “upfront + milestones” to:

• Cost-sharing mechanisms
• Profit-sharing modelsThis shift signifies that Chinese companies are no longer merely “technology providers,” but are becoming key players in the global R&D ecosystem.

For DengYueMed, such collaborations bring significantly more complex execution requirements—including cross-regional regulatory pathway design, synchronized multi-country supply chains, and quality system alignment.

III. Transformation of the Distributor’s Role

Within the broader narrative of innovative drug globalization, the distribution system is no longer just a logistics executor. For DengYueMed, the deepening of global healthcare collaboration requires capability upgrades across three key dimensions:

1. Regulatory Coordination Capability

As Chinese companies gain greater leadership in global projects, distributors must understand diverse regulatory frameworks and assist in complex dossier alignment, becoming a “regulatory navigator” for market entry.

2. Supply Chain Integration Capability

Innovative drugs demand the highest standards in cross-border warehousing, cold-chain logistics, and traceability. DengYueMed strengthens compliance management to ensure that every step—from “China-based manufacturing” to “global pharmacy delivery”—remains stable and controllable.

3. Market Entry Capability

In the 2.0 phase, Chinese companies increasingly retain overseas rights or participate in profit-sharing. Distributors must evolve from “trade execution” to “market entry enablers,” helping partners connect with local channels and achieve true commercial launch.

Conclusion

China’s innovative drug globalization in 2026 stands at a critical juncture, transitioning from Phase 2.0 toward 3.0. Whether it is Hengrui’s ADC platforms, Akeso’s bispecific antibodies, or Sino Biopharmaceutical’s first-in-class (FIC) small molecules, all are demonstrating that China has become an indispensable force in the global pharmaceutical innovation ecosystem.

For DengYueMed, the wave of global healthcare collaboration represents both opportunity and responsibility. We remain committed to serving as a strong bridge between “China Innovation” and the “Global Market,” leveraging professional cross-border supply chain capabilities to support compliant market entry and sustainable distribution of Chinese innovative drugs worldwide—contributing to the continued rise of China’s pharmaceutical industry on the global stage.